MASLD with Sven Francque - Part 2

What works in MASH now: weight loss, resmetirom, and semaglutide The 2024 EASL guidelines on MASLD are already out of date on treatment, and that's a good problem to have. In part 2, Pradeep Mundre and Professor Sven Francque (Antwerp), guideline co-author, walk through what works now. Lifestyle still earns the hardest numbers: 7% body weight loss for resolution of steatohepatitis, 10% for fibrosis regression. Resmetirom, a liver-targeted thyroid hormone receptor beta agonist, is now approved for F2-F3 fibrosis (though not in every EU country). Semaglutide has produced positive phase 3 data in MASH and an updated guideline is on the way. Sven...